AU2005282384B2 - Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment - Google Patents

Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment

Info

Publication number: AU2005282384B2
Authority: AU; Australia
Prior art keywords: cells; progenitor cells; composition; cell; conditioned medium
Prior art date: 2004-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2005282384A

Other languages

English (en)

Other versions

AU2005282384A1 (en

Inventor

Stephen E. Epstein

Shmuel Fuchs

Ran Kornowski

Martin B. Leon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Myocardial Therapeutics Inc

Original Assignee

Myocardial Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-08

Filing date

2005-09-07

Publication date

2011-09-01

2005-09-07 Application filed by Myocardial Therapeutics Inc filed Critical Myocardial Therapeutics Inc

2006-03-16 Publication of AU2005282384A1 publication Critical patent/AU2005282384A1/en

2011-09-01 Application granted granted Critical

2011-09-01 Publication of AU2005282384B2 publication Critical patent/AU2005282384B2/en

2025-09-07 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000003636 conditioned culture medium Substances 0.000 title claims abstract description 132
210000000130 stem cell Anatomy 0.000 title claims abstract description 123
230000033115 angiogenesis Effects 0.000 title claims abstract description 41
238000011282 treatment Methods 0.000 title description 21
210000004027 cell Anatomy 0.000 claims abstract description 149
210000001185 bone marrow Anatomy 0.000 claims abstract description 86
238000000034 method Methods 0.000 claims abstract description 64
210000001519 tissue Anatomy 0.000 claims abstract description 58
230000002491 angiogenic effect Effects 0.000 claims abstract description 50
239000000203 mixture Substances 0.000 claims abstract description 48
230000001225 therapeutic effect Effects 0.000 claims abstract description 29
230000028327 secretion Effects 0.000 claims abstract description 26
210000000577 adipose tissue Anatomy 0.000 claims abstract description 16
230000002093 peripheral effect Effects 0.000 claims abstract description 15
210000004369 blood Anatomy 0.000 claims abstract description 13
239000008280 blood Substances 0.000 claims abstract description 13
210000005259 peripheral blood Anatomy 0.000 claims abstract description 11
239000011886 peripheral blood Substances 0.000 claims abstract description 11
238000002347 injection Methods 0.000 claims description 46
239000007924 injection Substances 0.000 claims description 46
101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 42
102000000018 Chemokine CCL2 Human genes 0.000 claims description 42
239000002609 medium Substances 0.000 claims description 42
238000011161 development Methods 0.000 claims description 32
230000018109 developmental process Effects 0.000 claims description 32
210000002798 bone marrow cell Anatomy 0.000 claims description 30
230000002107 myocardial effect Effects 0.000 claims description 27
230000017531 blood circulation Effects 0.000 claims description 22
210000004204 blood vessel Anatomy 0.000 claims description 18
239000001963 growth medium Substances 0.000 claims description 18
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 17
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 17
206010021143 Hypoxia Diseases 0.000 claims description 17
108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 17
102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 16
230000001771 impaired effect Effects 0.000 claims description 14
230000007998 vessel formation Effects 0.000 claims description 13
102000008076 Angiogenic Proteins Human genes 0.000 claims description 12
108010074415 Angiogenic Proteins Proteins 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
210000003205 muscle Anatomy 0.000 claims description 12
230000004936 stimulating effect Effects 0.000 claims description 12
238000012258 culturing Methods 0.000 claims description 11
230000002708 enhancing effect Effects 0.000 claims description 11
210000002216 heart Anatomy 0.000 claims description 11
230000001146 hypoxic effect Effects 0.000 claims description 11
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 9
238000012545 processing Methods 0.000 claims description 9
230000000638 stimulation Effects 0.000 claims description 8
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 7
108091033319 polynucleotide Proteins 0.000 claims description 7
102000040430 polynucleotide Human genes 0.000 claims description 7
239000002157 polynucleotide Substances 0.000 claims description 7
-1 GM-CSF Proteins 0.000 claims description 6
101100244894 Sus scrofa PR39 gene Proteins 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
230000015624 blood vessel development Effects 0.000 claims description 4
230000007954 hypoxia Effects 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
229940126864 fibroblast growth factor Drugs 0.000 claims 4
210000001789 adipocyte Anatomy 0.000 claims 1
210000004976 peripheral blood cell Anatomy 0.000 claims 1
230000000302 ischemic effect Effects 0.000 abstract description 89
108090000623 proteins and genes Proteins 0.000 abstract description 76
102000004169 proteins and genes Human genes 0.000 abstract description 26
210000004165 myocardium Anatomy 0.000 abstract description 24
108700019146 Transgenes Proteins 0.000 abstract description 16
230000001737 promoting effect Effects 0.000 abstract description 3
238000003860 storage Methods 0.000 abstract description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 47
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 46
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 46
239000000047 product Substances 0.000 description 32
230000000694 effects Effects 0.000 description 31
230000014509 gene expression Effects 0.000 description 31
210000002889 endothelial cell Anatomy 0.000 description 30
102000004127 Cytokines Human genes 0.000 description 29
108090000695 Cytokines Proteins 0.000 description 29
230000035755 proliferation Effects 0.000 description 27
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 26
230000012010 growth Effects 0.000 description 24
230000001965 increasing effect Effects 0.000 description 23
230000010412 perfusion Effects 0.000 description 23
239000013598 vector Substances 0.000 description 23
239000003102 growth factor Substances 0.000 description 19
238000000338 in vitro Methods 0.000 description 18
241001465754 Metazoa Species 0.000 description 15
241000699670 Mus sp. Species 0.000 description 15
210000003141 lower extremity Anatomy 0.000 description 15
238000013459 approach Methods 0.000 description 14
210000003414 extremity Anatomy 0.000 description 14
239000002126 C01EB10 - Adenosine Substances 0.000 description 13
229960005305 adenosine Drugs 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
210000001616 monocyte Anatomy 0.000 description 13
241000701161 unidentified adenovirus Species 0.000 description 13
210000000329 smooth muscle myocyte Anatomy 0.000 description 11
241000282887 Suidae Species 0.000 description 10
230000001419 dependent effect Effects 0.000 description 10
210000002536 stromal cell Anatomy 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
239000002870 angiogenesis inducing agent Substances 0.000 description 9
230000006870 function Effects 0.000 description 9
238000001890 transfection Methods 0.000 description 9
238000012546 transfer Methods 0.000 description 9
238000002513 implantation Methods 0.000 description 8
238000001802 infusion Methods 0.000 description 8
230000002792 vascular Effects 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
108010016628 ameroid Proteins 0.000 description 7
210000002403 aortic endothelial cell Anatomy 0.000 description 7
230000003511 endothelial effect Effects 0.000 description 7
229960002897 heparin Drugs 0.000 description 7
229920000669 heparin Polymers 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
230000006698 induction Effects 0.000 description 7
208000028867 ischemia Diseases 0.000 description 7
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
230000008719 thickening Effects 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000004005 microsphere Substances 0.000 description 6
208000031225 myocardial ischemia Diseases 0.000 description 6
238000010899 nucleation Methods 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
230000008569 process Effects 0.000 description 6
108010054218 Factor VIII Proteins 0.000 description 5
102000001690 Factor VIII Human genes 0.000 description 5
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
229960000301 factor viii Drugs 0.000 description 5
210000001105 femoral artery Anatomy 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 5
210000002414 leg Anatomy 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
210000002027 skeletal muscle Anatomy 0.000 description 5
230000022379 skeletal muscle tissue development Effects 0.000 description 5
229910001220 stainless steel Inorganic materials 0.000 description 5
239000010935 stainless steel Substances 0.000 description 5
238000010361 transduction Methods 0.000 description 5
230000026683 transduction Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000004087 circulation Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000005090 green fluorescent protein Substances 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000010016 myocardial function Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 3
108010048154 Angiopoietin-1 Proteins 0.000 description 3
102000009088 Angiopoietin-1 Human genes 0.000 description 3
101150021185 FGF gene Proteins 0.000 description 3
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000032683 aging Effects 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
102000005936 beta-Galactosidase Human genes 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
230000006467 collateral growth Effects 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
208000031104 Arterial Occlusive disease Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101000851937 Homo sapiens Endothelial PAS domain-containing protein 1 Proteins 0.000 description 2
241001135569 Human adenovirus 5 Species 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
101150005851 NOS gene Proteins 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
206010047289 Ventricular extrasystoles Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000008649 adaptation response Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
210000001765 aortic valve Anatomy 0.000 description 2
208000021328 arterial occlusion Diseases 0.000 description 2
230000001623 arteriogenic effect Effects 0.000 description 2
230000027746 artery morphogenesis Effects 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000007667 floating Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
201000002818 limb ischemia Diseases 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000000998 lymphohematopoietic effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000003387 muscular Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
230000020874 response to hypoxia Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
210000004003 subcutaneous fat Anatomy 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
238000010967 transthoracic echocardiography Methods 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 1
101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241001092081 Carpenteria Species 0.000 description 1
101000573945 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP2 Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
101150081880 FGF1 gene Proteins 0.000 description 1
101150092822 FGF5 gene Proteins 0.000 description 1
208000036376 Femoral artery occlusion Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010018687 Granulocytopenia Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
101000661600 Homo sapiens Steryl-sulfatase Proteins 0.000 description 1
101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
102100035957 Huntingtin-interacting protein 1 Human genes 0.000 description 1
108050003304 Huntingtin-interacting protein 1 Proteins 0.000 description 1
102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
206010027905 Monocytopenia Diseases 0.000 description 1
101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101150018012 PR39 gene Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241001510071 Pyrrhocoridae Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
230000009471 action Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000006427 angiogenic response Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
238000003287 bathing Methods 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000009583 bone marrow aspiration Methods 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000018747 cellular response to hypoxia Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000006364 cellular survival Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000037011 constitutive activity Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000002586 coronary angiography Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
229940072645 coumadin Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002592 echocardiography Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940098448 fibroblast growth factor 7 Drugs 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000017323 hematopoietic stem cell migration to bone marrow Effects 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
102000050702 human PYCARD Human genes 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
230000007959 normoxia Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000004063 proteosomal degradation Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000006438 vascular health Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Marine Sciences & Fisheries (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2005282384A 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment Ceased AU2005282384B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US60827204P	2004-09-08	2004-09-08
US60/608,272		2004-09-08
PCT/US2005/031982 WO2006029262A2 (fr)	2004-09-08	2005-09-07	Support conditionne de cellules progenitrices autologues ou allogenes pour traitement de l'angiogenese

Publications (2)

Publication Number	Publication Date
AU2005282384A1 AU2005282384A1 (en)	2006-03-16
AU2005282384B2 true AU2005282384B2 (en)	2011-09-01

Family

ID=36036998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005282384A Ceased AU2005282384B2 (en)	2004-09-08	2005-09-07	Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment

Country Status (6)

Country	Link
EP (1)	EP1789538A2 (fr)
JP (1)	JP2008512198A (fr)
CN (1)	CN101432420A (fr)
AU (1)	AU2005282384B2 (fr)
CA (1)	CA2578815A1 (fr)
WO (1)	WO2006029262A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8021882B2 (en) *	2006-08-24	2011-09-20	Johnstone Brian H	Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
FI20085839A0 (fi) *	2008-09-08	2008-09-08	Timo Ylikomi	Menetelmiä ja välineitä pehmytkudosteknologiaan
US8911963B2 (en)	2010-04-05	2014-12-16	Medstar Health Research Institute, Inc.	Conditioned medium obtained from stem cells and its use in therapy
US11684574B2 (en)	2016-06-30	2023-06-27	University of Pittsburgh—of the Commonwealth System of Higher Education	Artificial cells and delivery devices for use in tissue engineering, and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000069449A2 (fr) *	1999-05-14	2000-11-23	Advanced Tissue Sciences, Inc.	Compositions de milieu de culture cellulaire conditionne et techniques d'utilisation
US20040131601A1 (en) *	2000-03-30	2004-07-08	Foundry Networks, Inc., A Delaward Corporation	Injection of bone marrow-derived cells and medium for angiogenesis

2005
- 2005-09-07 WO PCT/US2005/031982 patent/WO2006029262A2/fr not_active Ceased
- 2005-09-07 EP EP05796100A patent/EP1789538A2/fr not_active Withdrawn
- 2005-09-07 JP JP2007531326A patent/JP2008512198A/ja active Pending
- 2005-09-07 AU AU2005282384A patent/AU2005282384B2/en not_active Ceased
- 2005-09-07 CA CA002578815A patent/CA2578815A1/fr not_active Abandoned
- 2005-09-07 CN CNA2005800333013A patent/CN101432420A/zh active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000069449A2 (fr) *	1999-05-14	2000-11-23	Advanced Tissue Sciences, Inc.	Compositions de milieu de culture cellulaire conditionne et techniques d'utilisation
US20040131601A1 (en) *	2000-03-30	2004-07-08	Foundry Networks, Inc., A Delaward Corporation	Injection of bone marrow-derived cells and medium for angiogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REHMAN J et al, Circulation 2003, Vol. 107, pages 1164-1169 *

Also Published As

Publication number	Publication date
CA2578815A1 (fr)	2006-03-16
JP2008512198A (ja)	2008-04-24
CN101432420A (zh)	2009-05-13
EP1789538A2 (fr)	2007-05-30
WO2006029262A3 (fr)	2009-04-09
AU2005282384A1 (en)	2006-03-16
WO2006029262A2 (fr)	2006-03-16

Publication	Publication Date	Title
US20040131601A1 (en)	2004-07-08	Injection of bone marrow-derived cells and medium for angiogenesis
US7097832B1 (en)	2006-08-29	Intramyocardial injection of autologous bone marrow
US7135171B2 (en)	2006-11-14	Endothelial precursor cells for enhancing and restoring vascular function
EP2902483B1 (fr)	2020-03-11	Procédé de prolifération in vitro d'une population cellulaire contenant des cellules appropriées pour traiter une maladie ischémique
EP1171165B1 (fr)	2007-05-30	Injection intramyocardique de moelle osseuse autologue
KR101297145B1 (ko)	2013-08-21	줄기세포를 사용한 시험관내 기술
CA2487410C (fr)	2015-03-24	Injection intramyocardique de moelle osseuse autologue
AU2005282384B2 (en)	2011-09-01	Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
US20060057722A1 (en)	2006-03-16	Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
CN117919400B (zh)	2024-05-28	iPS诱导定向分化的成内皮祖细胞和抗体联合治疗心脑血管疾病
WO2005104766A2 (fr)	2005-11-10	Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese
US20060051334A1 (en)	2006-03-09	Injection of bone marrow-derived conditioned medium for angiogenesis
TW202242099A (zh)	2022-11-01	基因工程間充質幹細胞及其應用
WO2003070083A2 (fr)	2003-08-28	Cellules de precurseur endotheliales permettant d'ameliorer et de restaurer une fonction vasculaire
US20190382728A1 (en)	2019-12-19	Menstrual Blood Derived Angiogenesis Stimulatory Cells
Hendrickx et al.	2013	Cell and Gene Transfer Strategies for Vascularization During Skin Wound Healing

Legal Events

Date	Code	Title	Description
2011-03-31	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application
2011-04-07	TH	Corrigenda	Free format text: IN VOL 25, NO 13, PAGE(S) 1527 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2005 DELETE ALL REFERENCE TO 2005282384.
2012-01-12	FGA	Letters patent sealed or granted (standard patent)
2023-03-30	MK14	Patent ceased section 143(a) (annual fees not paid) or expired